Head-to-head evidence
Anhui HygeianCells EE001 vs HucMSC intramyocardial therapy
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
Anhui HygeianCells EE001
Developed by Anhui HygeianCells BioMedical
NCT06884111 · Phase 1 · completed
Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.
HucMSC intramyocardial therapy
Developed by Tasly Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07265349 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anhui HygeianCells EE001's landscape · HucMSC intramyocardial therapy's landscape